[xoo_el_inline_form active="login"]
Investment
Armed-T Product Pipeline
CytoArm owns >50 Armed T product rights for cancers and autoimmune diseases
1st Product: Armed T cell (CTA-02) for EGFR mutated colorectal cancer
Armed-T Product Pipeline
Licensing CTA-02 to big pharma after completion of 1st patient treatment
CytoArm Owns Complete Armed-T Patents
